[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mci-conversion-to-dementia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mci-conversion-to-dementia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100613916","neurocognitive-assessment-platform-4-alzheimer-100613916",false,"NCT07272811","Neurocognitive Assessment Platform 4 Alzheimer","NAP4A2020","Inclusion criteria common to both experimental groups:\n\n* Signature of informed consent\n* Age between 55 and 80 years\n* Absence of functional impact on daily living activities or minimal impact on instrumental activities\n\nSpecfic inclusion criteria for Healthy Controls recruitment:\n\n* Normal global cognitive efficiency (Mini Mental State Examination scores of 28 or higher)\n* Absence of specific cognitive deficits (memory and other cognitive domains) that are abnormal for age, sex, and education level (1.5 standard deviations below the mean for age- and education-matched controls), as assessed by objective, standardized cognitive tests.\n\nSpecific inclusion criteria for aMCI recruitment:\n\n* Cognitive difficulties reported by the individual, their family member, or their primary care physician\n* Normal global cognitive efficiency (Mini Mental State Examination score within 0.5 standard deviations of the average for age- and education-matched control subjects).\n* Specific cognitive deficits related to memory or multi-domain cognitive impairments (involving memory and other cognitive domains) that are atypical for the individual's age (1.5 standard deviations below the average for age- and education-matched controls), as determined by objective, standardized cognitive tests.\n\nExclusion Criteria:\n\n* Rejection of informed consent\n* Important sensory deficits (e.g., hearing loss or hypovisus)\n* Current or previous history of psychiatric illness\n* Current or previous degenerative pathology of the central nervous system (CNS)\n* Presence of systemic diseases in anamnesis\n* Presence of cerebrovascular events in anamnesis\n* Use of alcohol or psychotropic substances in anamnesis",true,"ALL","55 Years","80 Years",{"count":21,"type":22},100,"ESTIMATED","12 Months","OBSERVATIONAL","The aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050. In Italy, there are approximately 1.2 million cases of dementia, with 600,000 attributed to AD. Given the limited effectiveness of current pharmacological treatments, there is a growing need for early, non-pharmacological interventions to slow disease progression and improve the quality of life for patients and caregivers.\n\nThe Neurocognitive Assessment Platform 4 Alzheimer (NAP4A) study aims to create a digital platform for the early detection of amnestic mild cognitive impairment (MCIa), considered an intermediate stage between normal aging and dementia. The platform uses non-invasive biometric tools, including EEG, blood flow sensors, and eye-tracking devices, to collect neurophysiological and behavioral data.\n\nThe study will involve 100 participants aged 55 to 80, divided into two groups: one with individuals diagnosed with MCIa and a control group of healthy participants. Over 12 months, regular assessments will be conducted to identify markers that predict the progression from MCIa to AD. The goal is to develop advanced diagnostic tools that support early and targeted interventions.",[27,28,29,30],"MCI","MCI Conversion to Dementia","AMCI - Amnestic Mild Cognitive Impairment","Alzheimer Disease","RECRUITING","2026-01-20",{"date":34,"type":35},"2026-01-22","ACTUAL",{"date":37,"type":35},"2021-12-15",{"date":39,"type":22},"2026-06",{"name":41,"class":42},"IRCCS San Raffaele","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":43},"100492856","exploring-the-predicting-biomarkers-from-mild-cognitive-impairment-to-dementia-ebmid-100492856","NCT05697588","Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)","Studies on Biomarkers for Mild Cognitive Impairment Conversion to Dementia","Inclusion Criteria:\n\n* Male or female patients aged ≥50 and ≤85 years;\n\n  * Meet the diagnostic criteria for dementia or MCI; ③ Neuropsychological score: MMSE 15-28 points, CDR≤1 point; ④ The patients and their families were informed and signed the informed consent.\n\nExclusion Criteria:\n\n* There are other neurological diseases that can cause brain dysfunction (such as depression, brain tumors, Parkinson's disease disease, metabolic encephalopathy, encephalitis, multiple sclerosis, epilepsy, traumatic brain injury, normal intracranial pressure hydrocephalus, etc.);\n\n  * There are other systemic diseases that can cause cognitive impairment (such as hepatic insufficiency, renal insufficiency, Thyroid dysfunction, severe anemia, folic acid or vitamin B12 deficiency, syphilis, HIV infection, alcohol and drug abuse, etc.);\n\n    * Suffering from a disease that cannot cooperate with the completion of cognitive examination; ④ There are contraindications to nuclear magnetic resonance;\n\n      * There is mental and neurodevelopmental delay; ⑥ refuse to draw blood; ⑦ Refuse to sign the informed consent.","50 Years","85 Years",{"count":54,"type":22},900,"Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects more than 15% of the population over the age of 60 in China. About 15% patients with MCI could progress into dementia after two years and about one-third develop into dementia within five years, which will lead to suffering, as well as staggering economic and care burden. So, exploring the predicting biomarkers from MCI to dementia to identify and delay progression to dementia at an early stage is of great social and clinical significance. Some reports based on a single neural biomarker suggest that risk models can predict the conversion of MCI to dementia, but no widely recognized prediction models basing on multiple complex markers have been used in clinical practice. The objectives of this study are to outline the spectrum of MCI transforming into dementia through a 5-year prospective longitudinal cohort study; Secondly, screening biomarkers for MCI transmit to dementia are based on clinical symptoms, neuropsychology, neuroimaging, neuroelectrophysiology, and humoral markers tests data.",[57,28],"Biomarkers","2025-07-18",{"date":60,"type":35},"2025-07-24",{"date":62,"type":35},"2023-02-28",{"date":64,"type":22},"2028-02-28",{"name":66,"class":42},"Cuibai Wei，Clinical Professor"]